Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perceptiv (also known by its research code NF-02) is a multi-ingredient nutritional supplement formulation developed to support brain health and cognitive function, specifically in the context of Alzheimer's disease and age-related cognitive decline. Developed through research supported by the National Institute on Aging (NIA) and the University of Massachusetts Lowell, the formulation consists of a synergistic blend of six key nutrients: folic acid, vitamin B12, alpha-tocopherol (Vitamin E), S-adenosylmethionine (SAMe), N-acetyl cysteine (NAC), and acetyl-L-carnitine (ALCAR). The supplement is designed to address multiple neurodegenerative pathways by reducing oxidative stress, lowering homocysteine levels, maintaining healthy methylation cycles, and supporting mitochondrial energy production and neurotransmitter synthesis. Clinical evaluation in Phase 2 trials has demonstrated its potential to improve or stabilize cognitive performance and mood in patients with Alzheimer's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Perceptiv.